Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

Video

In Partnership With:

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Leisha A. Emens, MD, PhD, professor of medicine, Hematology/Oncology, co-leader, Hillman Cancer Immunology and Immunotherapy Program, director, Translational Immunotherapy for the Women’s Cancer Research Center, UPMC Hillman Cancer Center, discusses a potential future with immunotherapy in ovarian cancer.

It is understood that moving immunotherapy to the frontline setting elicits greater efficacy for women with ovarian cancer, explains Emens. Additionally, PD-L1—positive patients derive a greater benefit from the agents currently available in this space.

As such, the future of immunotherapy in ovarian cancer requires a good signal of activity with available agents. Clinical trials that incorporate biomarker analyses may allow investigators to better predict which patients are more likely to respond to this modality of treatment, concludes Emens.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,